The purpose of this study was to assess the effect of levodopa-carbidopa intestinal gel (carbidopa-levodopa enteral suspension) in advanced Parkinson’s disease patients with troublesome dyskinesia.
dyskinesia
Adenosine 2A Receptor Antagonists for the Treatment of Motor Symptoms in Parkinson’s Disease
Treatment of motor fluctuations in Parkinson’s disease (PD) remains an unmet challenge. Adenosine 2A (A2A) receptors are located along the indirect pathway and represent a potential target to enhance L-3,4-dihydroxyphenylalanine (L-DOPA) antiparkinsonian action.
Levodopa-carbidopa intestinal gel in advanced Parkinson’s disease: Final 12-month, open-label results
Motor complications in Parkinson’s disease (PD) are associated with long-term oral levodopa treatment and linked to pulsatile dopaminergic stimulation. L-dopa-carbidopa intestinal gel (LCIG) is delivered continuously by percutaneous endoscopic gastrojejunostomy tube (PEG-J), which reduces L-dopa-plasma–level fluctuations and can translate to reduced motor complications. We present final results of the largest international, prospective, 54-week, open-label LCIG study…
Clinical spectrum of levodopa-induced complications
The first years of Parkinson disease (PD) treatment are marked by good and sustained responses to dopaminergic therapy. With disease progression and longer exposure to levodopa (L-dopa), patients develop a range of L-dopa–induced complications that include motor and non-motor symptoms…
Randomized Trial of Safinamide Add-On to Levo dopa in Parkinson’s Disease With Motor Fluctuations
Levodopa is effective for the motor symptoms of Parkinson’s disease (PD), but is associated with motor fluctuations and dyskinesia. Many patients require add-on therapy to improve motor fluctuations without exacerbating dyskinesia. The objective of this Phase III, multicenter, double-blind, placebo-controlled, parallel-group study was to evaluate the efficacy and safety of safinamide…
